Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF‐II Immunoreactivity in Postmenopausal Women With Osteoporosis

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1359/jbmr.060314PMID 16753016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

  2005cited by this paper
• Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.

  2005cited by this paper
• Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters

  2005cited by this paper
• A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short‐Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide

  2005influential reference
• Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis.

  2004cited by this paper
• The elusive concept of bone quality

  2004influential reference
• The anabolic effects of GH/IGF system on bone.

  2004influential reference
• Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling

  2004influential reference
• Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose

  2004cited by this paper
• Trabecular minimodeling in human iliac bone.

  2003influential reference
• Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

  2003cited by this paper
• The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

  2003influential reference
• From Mouse to Man: Redefining the Role of Insulin-Like Growth Factor-I in the Acquisition of Bone Mass 1

  2003influential reference
• Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment.

  2003cited by this paper
• Size, structure and gender: lessons about fracture risk.

  2002cited by this paper
• Size, structure and gender: lessons about fracture risk.

  2002cited by this paper
• Biomechanics of Bone: Determinants of Skeletal Fragility and Bone Quality

  2002cited by this paper
• Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.

  2002cited by this paper
• Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety

  2002cited by this paper
• Circulating levels of IGF-1 directly regulate bone growth and density.

  2002influential reference
• Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study *

  2001influential reference
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Osteoporosis prevention, diagnosis, and therapy.

  2001cited by this paper
• Reconstructing the skeleton with intermittent parathyroid hormone.

  2001influential reference
• Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis.

  2000cited by this paper
• Down‐Regulation of the Serum Stimulatory Components of the Insulin‐like Growth Factor (IGF) System (IGF‐I, IGF‐II, IGF Binding Protein [BP]‐3, and IGFBP‐5) in Age‐Related (Type II) Femoral Neck Osteoporosis

  1999cited by this paper
• Anabolic effect of prostaglandin E2 on cortical bone of aged male rats comes mainly from modeling-dependent bone gain.

  1999cited by this paper
• Stimulation of Bone Formation In Vivo by Insulin-Like Growth Factor-II in Rats

  1998cited by this paper
• Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs.

  1998cited by this paper
• Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

  1997influential reference
• Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

  1997influential reference
• A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.

  1997influential reference
• Embedding of Bone Samples in Methylmethacrylate: An Improved Method Suitable for Bone Histomorphometry, Histochemistry, and Immunohistochemistry

  1997cited by this paper
• Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling?

  1996cited by this paper
• Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1–38) in right hindlimb immobilized rats

  1995cited by this paper
• Growth hormone, skeletal growth factors and osteoporosis.

  1995influential reference
• Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.

  1995influential reference
• An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.

  1993influential reference
• Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone

  1992influential reference
• Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces.

  1992influential reference
• Evidence that the inhibition of TE85 human bone cell proliferation by agents which stimulate cAMP production may in part be mediated by changes in the IGF-II regulatory system.

  1991cited by this paper
• hPTH 1–34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses

  1991influential reference
• Skeletal structural adaptations to mechanical usage (SATMU): 2. Redefining Wolff's Law: The remodeling problem

  1990cited by this paper
• Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff's Law: The bone modeling problem

  1990influential reference
• Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis.

  1990influential reference
• Resorption is not essential for the stimulation of bone growth by hPTH‐(1‐34) in rats in vivo

  1989influential reference
• Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers.

  1988cited by this paper
• Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

  1987cited by this paper
• Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

  1987cited by this paper
• Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease.

  1986cited by this paper
• Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle.

  1986cited by this paper
• Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss.

  1983influential reference
• Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

  1980influential reference

• Progress in Research on Medication‐Related Osteonecrosis of the Jaw: From Pathophysiological Mechanisms to Clinical Treatment

  2026cites this paper
• Parathyroid hormone receptor agonists in the management of osteoporosis

  2025influential citation
• Parathyroid Hormone (1–34) Signaling for Bone Health in Breast Cancer Survivorship and Metastasis

  2025cites this paper
• Confinement prevents postmenopausal osteoporosis and obesity via nuclear mechanical remodeling

  2025cites this paper
• Teriparatide in the Prevention and Treatment of Osteoporosis: an Update

  2025cites this paper
• FABP4 inhibition suppresses bone resorption and protects against postmenopausal osteoporosis in ovariectomized mice

  2025cites this paper
• The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans—a histomorphometry centered scoping review

  2025influential citation
• Acromion and Clavicle Stress Fractures After Reverse Total Shoulder Arthroplasty Reflect Failure to Address Osteoporosis: A Case Report and Literature Review

  2025cites this paper
• Long-term bisphosphonate use and femoral morphological changes in osteoporosis patients: a retrospective cohort study

  2025cites this paper
• Developing long bones respond to surrounding tissues by trans-pairing of periosteal osteoclasts and endocortical osteoblasts

  2024cites this paper
• Effectiveness of Weekly Teriparatide Injection in Postmenopausal Patients with Hip Fractures

  2023cites this paper
• Buds of new bone formation within the Femoral Head of Hip Fracture Patients Coincide with Zones of Low Osteocyte Sclerostin

  2023cites this paper
• Effects of high- vs. moderate-intensity intermittent training on parathyroid hormone concentration in overweight/obese females

  2023cites this paper
• Bone Remodeling and Modeling: Cellular Targets for Antiresorptive and Anabolic Treatments, Including Approaches Through the Parathyroid Hormone (PTH)/PTH-Related Protein Pathway

  2023cites this paper
• Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice.

  2022cites this paper
• Distinct Responses of Modeling‐ and Remodeling‐Based Bone Formation to the Discontinuation of Intermittent Parathyroid Hormone Treatment in Ovariectomized Rats

  2022cites this paper
• Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck.

  2022cites this paper
• Proceedings of the 2022 Santa Fe Bone Symposium: Current Concepts in the Care of Patients with Osteoporosis and Metabolic Bone Diseases.

  2022cites this paper
• Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis: Effects of teriparatide followed by denosumab.

  2022cites this paper
• New Frontiers in Osteoporosis Management: Optimizing Sequential and Combination Therapy

  2022cites this paper
• Role of teriparatide (rh PTH) in fracture healing of osteoporotic patient

  2022cites this paper
• Bone Health: Basic and Applied Bone Biology

  2022cites this paper
• Teriparatide

  2021cites this paper
• Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?

  2021cites this paper
• Activation, development, and attenuation of modeling- and remodeling-based bone formation in adult rats.

  2021cites this paper
• Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs

  2021cites this paper
• Physiological and Pharmacological Roles of PTH and PTHrP in Bone using their Shared Receptor, PTH1R.

  2021cites this paper
• Modeling‐Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial

  2021cites this paper
• Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives

  2021cites this paper
• Histochemical characteristics on minimodeling-based bone formation induced by anabolic drugs for osteoporotic treatment.

  2021influential citation
• Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis

  2021cites this paper
• Histomorphometry of Remodeling and Modeling-Based Mineral Apposition

  2021cites this paper
• Mechanical Loading and Parathyroid Hormone Effects and Synergism in Bone Vary by Site and Modeling/Remodeling Regime.

  2021cites this paper
• ASPECTS OF INTERCELLULAR COMMUNICATION IN BONE AND IMPLICATIONS IN THERAPY.

  2021cites this paper
• Bone Remodeling and Modeling: Therapeutic Targets for the Treatment of Osteoporosis

  2021cites this paper
• The Effect of Teriparatide on the Hip: A Literature Review

  2021cites this paper
• Histomorphometric analysis of bone remodeling

  2020cites this paper
• Role of Gut Microbiota in the Skeletal Response to PTH

  2020cites this paper
• Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis

  2020cites this paper
• Parathyroid Hormones

  2020cites this paper
• Coadministration of zoledronic acid and teriparatide in postmenopausal osteoporosis

  2020cites this paper
• Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab

  2020cites this paper
• Pharmacologic mechanisms of therapeutics

  2020cites this paper
• Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT.

  2020cites this paper
• Effects of Combination Denosumab and High‐Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA‐HD HR‐pQCT Study

  2020cites this paper
• Cellular actions of parathyroid hormone on bone

  2020cites this paper
• Paracrine parathyroid hormone–related protein in bone: physiology and pharmacology

  2020cites this paper
• Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial

  2020cites this paper
• Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy.

  2020cites this paper
• Antiresorptive and anabolic agents in the prevention and reversal of bone fragility

  2019cites this paper
• PTH as An Anabolic Agent

  2019cites this paper
• Interaction among Calcium Diet Content, PTH (1-34) Treatment and Balance of Bone Homeostasis in Rat Model: The Trabecular Bone as Keystone

  2019cites this paper
• Teriparatide (recombinant human parathyroid hormone [1‐34]) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double‐blind placebo‐controlled study

  2019cites this paper
• Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

  2019cites this paper
• [Anabolic action of teriparatide to osteoporotic patients].

  2019cites this paper
• Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study

  2018cites this paper
• Antiosteoporotic effects of 3:1 (g/g) mixed formulation of exopolymers purified from Aureobasidium pullulans SM‐2001 and Dendropanax morbifera leaf extracts in ovariectomized rats

  2018cites this paper
• Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study

  2018influential citation
• Effects of Parathyroid Hormone, Alendronate and Odanacatib on the mineralisation process in intracortical and endocortical Haversian bone of ovariectomized rabbits

  2018cites this paper
• Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling‐ and Remodeling‐Based Formation in the SHOTZ Study

  2018influential citation
• Differing Effects of Parathyroid Hormone, Alendronate, and Odanacatib on Bone Formation and on the Mineralization Process in Intracortical and Endocortical Bone of Ovariectomized Rabbits

  2018cites this paper
• Histological Effects of the Combined Administration of Eldecalcitol and a Parathyroid Hormone in the Metaphyseal Trabeculae of Ovariectomized Rats

  2018cites this paper
• The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration

  2018cites this paper
• The effects of sclerostin antibody plus parathyroid hormone (1–34) on bone formation in ovariectomized rats

  2018cites this paper
• Evidence for Ongoing Modeling-Based Bone Formation in Human Femoral Head Trabeculae via Forming Minimodeling Structures: A Study in Patients with Fractures and Arthritis

  2018cites this paper
• Intermittent parathyroid hormone improve bone microarchitecture of the mandible and femoral head in ovariectomized rats

  2017cites this paper
• Parathyroid Hormone (1-34) Might Not Improve Early Bone Healing after Sinus Augmentation in Healthy Rabbits

  2017cites this paper
• Syddansk Universitet Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture Final Results of a 78-Week Randomized Clinical Trial

  2017cites this paper
• Parathyroid hormone 1-34 and skeletal anabolic action

  2017cites this paper
• Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78‐Week Randomized Clinical Trial

  2017cites this paper
• PTH(1‐34) effects on repairing experimentally drilled holes in rat femur: novel aspects – qualitative vs. quantitative improvement of osteogenesis

  2017influential citation
• Intermittent administration of parathyroid hormone ameliorated alveolar bone loss in experimental periodontitis in streptozotocin-induced diabetic rats.

  2017cites this paper
• University of Southern Denmark Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture Final Results of a 78-Week Randomized Clinical Trial

  2017cites this paper
• Retrospective radiological outcome analysis following teriparatide use in elderly patients undergoing multilevel instrumented lumbar fusion surgery

  2017cites this paper
• Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.

  2017cites this paper
• Abaloparatide Is an Anabolic, but Does It Spare Resorption?

  2017influential citation
• Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

  2017cites this paper
• Bisphosphonate Pre-Treatment Diminishes the Therapeutic Benefits of Teriparatide in Japanese Osteoporotic Patients.

  2016cites this paper
• A Novel Human PTH Analog [Cys25]hPTH(1-34) Restores Bone Mass in Ovariectomized Mice.

  2016cites this paper
• The Relationship of BMD Increases Between the First 12 Months and the Latter 12 Months by Daily Teriparatide Treatment

  2016cites this paper
• Teriparatide and denosumab combination therapy and skeletal metabolism

  2016cites this paper
• Investigating the effects of downstream parathyroid hormone (PTH) targets on bone strength and quality

  2016cites this paper
• Coupling: The Influences of Immune and Bone Cells

  2016cites this paper
• Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation.

  2016cites this paper
• Frequency of Teriparatide Administration Affects the Histological Pattern of Bone Formation in Young Adult Male Mice.

  2016cites this paper
• Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.

  2016cites this paper
• Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.

  2016cites this paper
• Skeletal Adaptation to Mechanical Strain: A Key Role in Osteoporosis

  2016cites this paper
• Histomorphometric analysis of minimodeling in the vertebrae in postmenopausal patients treated with anti-osteoporotic agents

  2016cites this paper
• Oestrogen and parathyroid hormone alleviate lumbar intervertebral disc degeneration in ovariectomized rats and enhance Wnt/β-catenin pathway activity

  2016cites this paper
• Teriparatide for osteoporosis: importance of the full course

  2016cites this paper
• ANNALS OF THE NEW YORK ACADEMY OF SCIENCES MARROW

  2016cites this paper
• T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone

  2016cites this paper
• A 4D imaging approach to monitor bone remodeling

  2016cites this paper
• Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases.

  2016cites this paper
• Applications of Teriparatide for Fracture Repair and Osteosynthetic Surgery in Osteoporosis

  2016cites this paper
• Parathyroid hormone: anabolic and catabolic actions on the skeleton.

  2015cites this paper
• Improvement of Skeletal Fragility by Teriparatide in Adult Osteoporosis Patients: A Novel Mechanostat-Based Hypothesis for Bone Quality

  2015influential citation
• Co‐administration of Antiresorptive and Anabolic Agents: A Missed Opportunity

  2015cites this paper
• Abaloparatide: a new anabolic therapy on the horizon.

  2015cites this paper